Unfavorable drug interactions in targeted breast cancer therapy

2Citations
Citations of this article
29Readers
Mendeley users who have this article in their library.

Abstract

Trastuzumab is used to treat HER2-positive breast cancer; erythropoietin (EPO) is used to alleviate chemotherapy-associated side effects. In this issue of Cancer Cell, Liang et al. show that many breast tumors express EPO receptor (EpoR), whose activation by EPO recovers signaling pathways downregulated by trastuzumab, thereby blunting trastuzumab's therapeutic effect. © 2010 Elsevier Inc.

Cite

CITATION STYLE

APA

Groner, B., & Hynes, N. E. (2010, November 16). Unfavorable drug interactions in targeted breast cancer therapy. Cancer Cell. https://doi.org/10.1016/j.ccr.2010.10.027

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free